Definition and management of ruxolitinib treatment failure in myelofibrosis.
about
JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indicationsA phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosisManagement of myelofibrosis: JAK inhibition and beyond.Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent mannerRecommendations on the use of ruxolitinib for the treatment of myelofibrosis.Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.The use of JAK inhibitors for low-risk myelofibrosis.
P2860
Q26782539-23966CA1-4626-4C25-9CF2-0CDCEAF45644Q33434284-13A81D7D-BE0B-4D0D-B08D-E3BB7EB74A0BQ39232415-A7428465-B279-4A2C-AFB1-FB4CCA9619E1Q40085126-A8BFADDE-4382-469B-99F4-970CD5584157Q41553248-E7F3B4A8-2E39-44A1-9D8F-B08CFFDF9D36Q47815810-52470928-8A5C-4088-9D0B-2B79C481F774Q51742255-189911AB-7F7C-43A6-9FF9-D8A5C1FD081DQ55043645-1DB907CC-668D-4E64-BDAF-2687A80184BB
P2860
Definition and management of ruxolitinib treatment failure in myelofibrosis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Definition and management of ruxolitinib treatment failure in myelofibrosis.
@en
type
label
Definition and management of ruxolitinib treatment failure in myelofibrosis.
@en
prefLabel
Definition and management of ruxolitinib treatment failure in myelofibrosis.
@en
P2860
P356
P1433
P1476
Definition and management of ruxolitinib treatment failure in myelofibrosis.
@en
P2093
A Pardanani
P2860
P2888
P356
10.1038/BCJ.2014.84
P5008
P577
2014-12-12T00:00:00Z
P5875
P6179
1037300730